EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Masitinib Inhibits Hepatitis A Virus Replication

Reina Sasaki-Tanaka iD, Toshikatsu Shibata, Mitsuhiko Moriyama iD, Hirofumi Kogure iD, Asuka Hirai-Yuki, Hiroaki Okamoto iD, Tatsuo Kanda iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24119708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Reina Sasaki-Tanaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 1…. Hauptthemen laut MEDLINE: Hepatitis A, Hepatitis A virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Platform Project for Supporting Drug Discovery and Life Science Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The hepatitis A virus (HAV) infection causes acute hepatitis. HAV also induces acute liver failure or acute-on-chronic liver failure; however, no potent anti-HAV drugs are currently available in clinical situations. For anti-HAV drug screening, more convenient and useful models that mimic HAV replication are needed. In the present study, we established HuhT7-HAV/Luc cells, which are HuhT7 cells stably expressing the HAV HM175-18f genotype IB subgenomic replicon RNA harboring the firefly luciferase gene. This system was made by using a PiggyBac-based gene transfer system that introduces nonviral transposon DNA into mammalian cells. Then, we investigated whether 1134 US Food and Drug Administration (FDA)-approved drugs exhibited in vitro anti-HAV activity. We further demonstrated that treatment with tyrosine kinase inhibitor masitinib significantly reduced both HAV HM175-18f genotype IB replication and HAV HA11-1299 genotype IIIA replication. Masitinib also significantly inhibited HAV HM175 internal ribosomal entry-site (IRES) activity. In conclusion, HuhT7-HAV/Luc cells are adequate for anti-HAV drug screening, and masitinib may be useful for the treatment of severe HAV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis AHepatitis A virusHumansHepatitis A AntibodiesProtein BiosynthesisRNA, ViralVirus ReplicationSubgenomic RNABenzamidesPiperidinesPyridinesThiazoles

Stichwörter der Autor:innen

HAVHAV stable repliconHuhT7 cellsdrug screeningmasitinib

Substanzen

Hepatitis A AntibodiesRNA, ViralSubgenomic RNAmasitinibBenzamidesPiperidinesPyridinesThiazoles

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
  • Division of Experimental Animal Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Tochigi 329-0498, Japan.

ORCID-Profile: Reina Sasaki-Tanaka, Mitsuhiko Moriyama, Hirofumi Kogure, Hiroaki Okamoto, Tatsuo Kanda

Förderung

  • Japan Agency for Medical Research and Development
  • Platform Project for Supporting Drug Discovery and Life Science Research

Zitieren

APA

Sasaki-Tanaka, R., Shibata, T., Moriyama, M., Kogure, H., Hirai-Yuki, A., Okamoto, H., & Kanda, T. (2023). Masitinib Inhibits Hepatitis A Virus Replication. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119708

Vancouver

Sasaki-Tanaka R, Shibata T, Moriyama M, Kogure H, Hirai-Yuki A, Okamoto H, et al. Masitinib Inhibits Hepatitis A Virus Replication. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119708

BibTeX
@article{SasakiTanaka2023,
  author = {Sasaki-Tanaka, Reina and Shibata, Toshikatsu and Moriyama, Mitsuhiko and Kogure, Hirofumi and Hirai-Yuki, Asuka and Okamoto, Hiroaki and Kanda, Tatsuo},
  title = {Masitinib Inhibits Hepatitis A Virus Replication},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24119708}
}
Kostenlos starten →